文献速递头颈与中枢神经肿瘤

可植入超声装置重复开放血脑屏障递送白蛋白结合型紫杉醇治疗复发性胶质母细胞瘤的1期试验

Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial.
PubMed 文献 · Lancet Oncol · 2023-01-01

这项1期剂量递增试验在17例复发性胶质母细胞瘤患者中评估低强度脉冲超声联合微泡(LIPU-MB)开放血脑屏障递送白蛋白结合型紫杉醇的安全性与药代动力学。260 mg/m2剂量下1例(8%)出现3级脑病(剂量限制性毒性),药代动力学显示声处理脑区白蛋白结合型紫杉醇浓度较未声处理区升高3.7倍(p<0.0001)。结论认为LIPU-MB可安全重复开放血脑屏障使细胞毒药物入脑,已启动2期试验。

要点

  • 260 mg/m2剂量下1例(8%)出现3级脑病(剂量限制性毒性),停药减量后缓解。
  • LIPU-MB最常见不良事件为即刻短暂1-2级头痛(12/17,71%)。
  • 声处理脑区白蛋白结合型紫杉醇浓度较未声处理区升高3.7倍(p<0.0001)。

核心结论

  • LIPU-MB使用颅骨植入式超声装置可短暂开放血脑屏障,使细胞毒药物安全、重复地渗透入脑。
  • 本研究已促成后续2期试验(NCT04528680),联合LIPU-MB与白蛋白结合型紫杉醇加卡铂,正在进行中。

研究设计与样本

  • 剂量递增1期临床试验,纳入年龄≥18岁、肿瘤直径≤70 mm、卡氏功能状态评分≥70的复发性胶质母细胞瘤成人患者。
  • 肿瘤切除后于颅骨窗植入九发射器超声装置,每3周行LIPU-MB联合静脉白蛋白结合型紫杉醇输注,最多6个周期。
  • 评估6个白蛋白结合型紫杉醇剂量水平:40、80、135、175、215和260 mg/m2。
  • 主要终点为首次声处理及白蛋白结合型紫杉醇化疗周期内发生的剂量限制性毒性;安全性分析纳入所有治疗患者,分析在符合方案人群中进行。
  • 2020年10月29日至2022年2月21日共入组17例患者(男9例,女8例);数据截止2022年9月6日,中位随访11.89个月(IQR 11.12-12.78)。

主要发现

  • 剂量水平1至5(40-215 mg/m2)各治疗1例患者,剂量水平6(260 mg/m2)治疗12例患者;共完成68个周期LIPU-MB血脑屏障开放(每例中位3周期,范围2-6)。
  • 260 mg/m2剂量下,1例(8%,1/12)在首次周期发生3级脑病(判定为剂量限制性毒性),另1例在第二周期发生2级脑病;两例毒性均缓解并减量继续治疗,3级脑病减至175 mg/m2,2级脑病减至215 mg/m2。
  • 1例患者在260 mg/m2白蛋白结合型紫杉醇第三周期出现2级周围神经病;未观察到归因于LIPU-MB的进行性神经功能缺损。
  • LIPU-MB相关血脑屏障开放最常见为即刻短暂1-2级头痛(17例中12例,71%);最常见3-4级治疗中出现的不良事件为中性粒细胞减少(8例,47%)、白细胞减少(5例,29%)和高血压(5例,29%);研究期间无治疗相关死亡。
  • 影像分析显示LIPU-MB靶向脑区血脑屏障开放,声处理后1小时内减弱。

关键数值与推荐

  • 剂量限制性毒性:260 mg/m2剂量下首次周期3级脑病1例(8%,1/12)。
  • 白蛋白结合型紫杉醇脑实质浓度:非声处理区0.037 μM(95% CI 0.022-0.063) vs 声处理区0.139 μM(95% CI 0.083-0.232),升高3.7倍,p<0.0001。
  • 卡铂脑实质浓度:非声处理区0.991 μM(95% CI 0.562-1.747) vs 声处理区5.878 μM(95% CI 3.462-9.980),升高5.9倍,p=0.0001。

临床怎么用

  • 原文未据此给出临床推荐。
  • 作者指出本研究已促成正在进行的2期试验,联合LIPU-MB与白蛋白结合型紫杉醇加卡铂(NCT04528680)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low-intensity pulsed ultrasound with concomitant administration of intravenous microbubbles (LIPU-MB) can be used to open the blood-brain barrier. We aimed to assess the safety and pharmacokinetics of LIPU-MB to enhance the delivery of albumin-bound paclitaxel to the peritumoural brain of patients with recurrent glioblastoma. METHODS: We conducted a dose-escalation phase 1 clinical trial in adults (aged ≥18 years) with recurrent glioblastoma, a tumour diameter of 70 mm or smaller, and a Karnofsky performance status of at least 70. A nine-emitter ultrasound device was implanted into a skull window after tumour resection. LIPU-MB with intravenous albumin-bound paclitaxel infusion was done every 3 weeks for up to six cycles. Six dose levels of albumin-bound paclitaxel (40 mg/m2, 80 mg/m2, 135 mg/m2, 175 mg/m2, 215 mg/m2, and 260 mg/m2) were evaluated. The primary endpoint was dose-limiting toxicity occurring during the first cycle of sonication and albumin-bound paclitaxel chemotherapy. Safety was assessed in all treated patients. Analyses were done in the per-protocol population. Blood-brain barrier opening was investigated by MRI before and after sonication. We also did pharmacokinetic analyses of LIPU-MB in a subgroup of patients from the current study and a subgroup of patients who received carboplatin as part of a similar trial (NCT03744026). This study is registered with ClinicalTrials.gov, NCT04528680, and a phase 2 trial is currently open for accrual. FINDINGS: 17 patients (nine men and eight women) were enrolled between Oct 29, 2020, and Feb 21, 2022. As of data cutoff on Sept 6, 2022, median follow-up was 11·89 months (IQR 11·12-12·78). One patient was treated per dose level of albumin-bound paclitaxel for levels 1 to 5 (40-215 mg/m2), and 12 patients were treated at dose level 6 (260 mg/m2). A total of 68 cycles of LIPU-MB-based blood-brain barrier opening were done (median 3 cycles per patient [range 2-6]). At a dose of 260 mg/m2, encephalopathy (grade 3) occurred in one (8%) of 12 patients during the first cycle (considered a dose-limiting toxicity), and in one other patient during the second cycle (grade 2). In both cases, the toxicity resolved and treatment continued at a lower dose of albumin-bound paclitaxel, with a dose of 175 mg/m2 in the case of the grade 3 encephalopathy, and to 215 mg/m2 in the case of the grade 2 encephalopathy. Grade 2 peripheral neuropathy was observed in one patient during the third cycle of 260 mg/m2 albumin-bound paclitaxel. No progressive neurological deficits attributed to LIPU-MB were observed. LIPU-MB-based blood-brain barrier opening was most commonly associated with immediate yet transient grade 1-2 headache (12 [71%] of 17 patients). The most common grade 3-4 treatment-emergent adverse events were neutropenia (eight [47%]), leukopenia (five [29%]), and hypertension (five [29%]). No treatment-related deaths occurred during the study. Imaging analysis showed blood-brain barrier opening in the brain regions targeted by LIPU-MB, which diminished over the first 1 h after sonication. Pharmacokinetic analyses showed that LIPU-MB led to increases in the mean brain parenchymal concentrations of albumin-bound paclitaxel (from 0·037 μM [95% CI 0·022-0·063] in non-sonicated brain to 0·139 μM [0·083-0·232] in sonicated brain [3·7-times increase], p<0·0001) and carboplatin (from 0·991 μM [0·562-1·747] in non-sonicated brain to 5·878 μM [3·462-9·980] μM in sonicated brain [5·9-times increase], p=0·0001). INTERPRETATION: LIPU-MB using a skull-implantable ultrasound device transiently opens the blood-brain barrier allowing for safe, repeated penetration of cytotoxic drugs into the brain. This study has prompted a subsequent phase 2 study combining LIPU-MB with albumin-bound paclitaxel plus carboplatin (NCT04528680), which is ongoing. FUNDING: National Institutes of Health and National Cancer Institute, Moceri Family Foundation, and the Panattoni family.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Sonabend AM, Gould A, Amidei C, et al. Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol. 2023. PMID: 37142373. doi:10.1016/S1470-2045(23)00112-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。